Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02631746 · ClinicalTrials.gov registry record · Phase 2
Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT02631746: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT02631746 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02631746, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This phase II trial studies how well nivolumab works in treating patients with human T-cell leukemia virus (HTLV)-associated T-cell leukemia/lymphoma. Nivolumab is an antibody, which is a type of blood protein that tags infected cells and other harmful agents. Nivolumab works against a protein called programmed cell death (PD)-1 and may help the body destroy cancer cells by helping the immune system to keep fighting cancer.
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Nivolumab
- OTHER Pharmacogenomic Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2017-02-23 |
| Est. Completion | 2019-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02631746
The ClinicalTrials.gov registry entry for NCT02631746 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02631746 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02631746 about?
NCT02631746 is a clinical study titled "Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma". This phase II trial studies how well nivolumab works in treating patients with human T-cell leukemia virus (HTLV)-associated T-cell leukemia/lymphoma. Nivolumab is an antibody, which is a type of blood protein that tags infected cells and other harmful agents. Nivolumab works against a protein calle...
What is the current status of trial NCT02631746?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2017-02-23. Estimated completion is 2019-07-31.
What interventions are being tested in trial NCT02631746?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Nivolumab (BIOLOGICAL), Pharmacogenomic Study (OTHER).
Who is sponsoring clinical trial NCT02631746?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.